Syn­er­gy Phar­ma preps step 2 for Tru­lance as pos­i­tive PhI­II IBS-C da­ta squares off against Iron­wood and Arde­lyx

Hot on the heels for an ap­proval of Tru­lance (ple­ca­natide) for chron­ic id­io­path­ic con­sti­pa­tion, Syn­er­gy Phar­ma $SGYP is back with pos­i­tive Phase III da­ta on ir­ri­ta­ble bow­el syn­drome, which will quick­ly trig­ger some com­par­isons with a well-es­tab­lished drug in the mar­ket as well as a late-stage drug com­ing up close be­hind.

In­ves­ti­ga­tors say that Tru­lance scored the pri­ma­ry end­point in two large stud­ies in­volv­ing 2,100 pa­tients with IBS in­volv­ing con­sti­pa­tion. Over­all re­spon­ders — those pa­tients who achieved a sig­nif­i­cant re­duc­tion in the worst ab­dom­i­nal pain along with a sig­nif­i­cant in­crease in bow­el move­ments over 6 of 12 weeks — in both dose groups out­paced the place­bo arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER